Latest Articles
Endometrial Cancer: Sequencing Lenvatinib–Pembrolizumab - Alignment with Trials, Post-Adjuvant Potential, and Dose Flexibility - OncLive
Endometrial Cancer: Sequencing Lenvatinib–Pembrolizumab - Alignment with Trials, Post-Adjuvant Potential, and Dose Flexibility OncLive
Published: Jan. 2, 2026, 1:12 p.m.
Endometrial Cancer: Framing Prognosis, Weaving Clinical Trials and Real-World Data into Patient Conversations - OncLive
Endometrial Cancer: Framing Prognosis, Weaving Clinical Trials and Real-World Data into Patient Conversations OncLive
Published: Jan. 2, 2026, 1:10 p.m.
Study Identifies E2F8 as Key Regulator of DTL and MAPK Pathway in Endometrial Cancer Progression - geneonline.com
Study Identifies E2F8 as Key Regulator of DTL and MAPK Pathway in Endometrial Cancer Progression geneonline.com
Published: Dec. 30, 2025, 4:33 a.m.
E2F8 Boosts DTL, Driving Endometrial Cancer via MAPK - Bioengineer.org
E2F8 Boosts DTL, Driving Endometrial Cancer via MAPK Bioengineer.org
Published: Dec. 30, 2025, 3:47 a.m.
E2F8 Boosts DTL, Driving Endometrial Cancer via MAPK - BIOENGINEER.ORG
E2F8 Boosts DTL, Driving Endometrial Cancer via MAPK BIOENGINEER.ORG
Published: Dec. 30, 2025, 3:47 a.m.
Rising rates of endometrial cancer prompt new research - SDPB
Rising rates of endometrial cancer prompt new research SDPB
Published: Dec. 29, 2025, 9:30 a.m.
Mali Barbi: Moving Beyond the “One-Size-Fits-All” Era in Endometrial Cancer - Oncodaily
Mali Barbi: Moving Beyond the “One-Size-Fits-All” Era in Endometrial Cancer Oncodaily
Published: Dec. 27, 2025, 7:14 p.m.
Endometrial Cancer: Toxicity Management and Treatment Persistence with Lenvatinib-Pembrolizumab - OncLive
Endometrial Cancer: Toxicity Management and Treatment Persistence with Lenvatinib-Pembrolizumab OncLive
Published: Dec. 26, 2025, 1:19 p.m.
Endometrial Cancer: Counseling on dMMR vs pMMR - Explaining Survival Advantage and Clinical Expectations - OncLive
Endometrial Cancer: Counseling on dMMR vs pMMR - Explaining Survival Advantage and Clinical Expectations OncLive
Published: Dec. 26, 2025, 1:19 p.m.
After comparing endometrial cancer minimally invasive surgery, laparotomy, survival rate and complications... - MSN
After comparing endometrial cancer minimally invasive surgery, laparotomy, survival rate and complications... MSN
Published: Dec. 25, 2025, 7:50 p.m.
Link copied to clipboard!